ReviewHealth science reports2026
Biomarkers for Early Detection of Diabetic Kidney Disease in Pediatric and Adolescent Populations: A Narrative Review.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy is among the most critical long-term complications linked to diabetes, substantially influencing both morbidity and mortality. Although it was once largely associated with adults, diabetic kidney disease (DKD) has now become a leading source of kidney complications among children worldwide. Acting as both an indicator and predictor of cardiovascular complications and end-stage kidney disease (ESKD), DKD in pediatric diabetic patients is of increasing concern. Methods: This study was conducted as a narrative review of the literature focusing on emerging biomarkers for the early detection of diabetic kidney disease in pediatric and adolescent populations. Results: Traditionally, microalbuminuria assessed through spot urine samples remains the standard method for identifying early kidney involvement in patients with diabetes. However, growing evidence suggests that renal tubular injury often precedes overt glomerular damage, particularly in pediatric and adolescent populations. This highlights the potential value of tubular biomarkers, such as neutrophil gelatinase‑associated lipocalin (NGAL) and kidney injury molecule‑1 (KIM‑1), which may detect subclinical kidney injury before the onset of persistent albuminuria. Emerging biomarkers, including cystatin C, liver‑type fatty acid‑binding protein (L‑FABP), inflammatory mediators, and metabolic markers, may further improve the early identification and risk stratification of diabetic kidney disease, enabling timely intervention and personalized monitoring strategies in children and adolescents with diabetes. Conclusion: Identifying new biomarkers for early-stage kidney involvement in diabetic youth could significantly enhance timely diagnosis and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.